Poor prognostic factors for OS, LRR, or DM determined in patients with breast cancer receiving TM in the present study, namely, moderate-poor differentiation, advanced clinical stages, advanced pathologic TN stages, HER2 positivity, adjuvant RT, and adjuvant chemotherapy (Tables 2–4), are similar to those reported in previous studies (57–61). Here, ERBB2 is linked to breast carcinoma.